Guo Lei, Fujino Masayuki, Kimura Hiromitsu, Funeshima Naoko, Kitazawa Yusuke, Harihara Yasushi, Tezuka Katsunari, Makuuchi Masatoshi, Suzuki Seiichi, Li Xiao-Kang
Laboratory of Transplantation Immunology, Department of Innovative Surgery, National Research Institute for Child Health and Development, 3-35-31 Taishido, Setagaya-ku, Tokyo 154-8567, Japan.
Transpl Immunol. 2003 Oct-Nov;12(1):41-8. doi: 10.1016/S0966-3274(03)00016-9.
An inducible co-stimulator (ICOS), a recently identified co-stimulatory receptor with a close structural homology of CD28 and CTLA4, is expressed on activated T cells. Anti-ICOS antibody was demonstrated to be effective on prolongation of graft survival after liver transplantation in rats. In this study, we investigated the potency of tolerance induction using the antibody combined with a recombinant adenovirus vector containing CTLA-4Ig cDNA (AdCTLA-4Ig) in rat heart transplantation model. Using a DA-to-Lewis rat heart transplantation model, an anti-rat ICOS antibody and AdCTLA-4Ig were simultaneously administered i.v. into recipients. The tissue specimens from the grafts were removed on various days after transplantation for histological evaluation. Donor-strain skin and heart grafts, and third-party heart allografts were challenged in the recipients with a long-term surviving graft. Splenocytes from the tolerance-induced recipients were used for adoptive transfer study. Anti-ICOS antibody alone did not prolong the survival of heart allograft. AdCTLA-4Ig monotherapy significantly prolonged the survival of heart allograft (Group 4). With a combination of Anti-ICOS antibody and AdCTLA-4Ig, all recipients were resulted in a long-term allograft acceptance for more than 200 days (Group 8). When challenged donor-strain skin grafts in the tolerant rats of Group 4, the skin was rejected, which also lead to a rejection of primary heart allografts. The recipients in Group 8 also rejected donor-strain skin grafts with no rejection of the primary heart grafts. These recipients accepted secondary heart grafts from donor-strain but not third-party. In Group 8 long-term survival recipients showed a high population of CD4+CD25+ regulatory T cell in peripheral blood, and in adoptive transfer study subtraction of these CD4+CD25+ T cells accelerate the rejection of heart graft in secondary irradiated recipients. The present results demonstrated that anti-ICOS antibody combined with AdCTLA-4Ig potently induces a stable immune tolerance after heart allografting in rat, which is mediated by the induction of CD4+CD25+ regulatory T cells. This strategy may be attractive for clinical employment to induce transplantation tolerance.
诱导性共刺激分子(ICOS)是一种最近发现的共刺激受体,与CD28和CTLA4在结构上有密切的同源性,表达于活化的T细胞上。抗ICOS抗体已被证明在延长大鼠肝移植后的移植物存活方面有效。在本研究中,我们在大鼠心脏移植模型中研究了使用该抗体与含有CTLA-4Ig cDNA的重组腺病毒载体(AdCTLA-4Ig)联合诱导耐受的效力。使用DA到Lewis大鼠心脏移植模型,将抗大鼠ICOS抗体和AdCTLA-4Ig同时静脉注射给受体。在移植后的不同天数取出移植物的组织标本进行组织学评估。用长期存活的移植物对受体进行供体品系皮肤和心脏移植物以及第三方心脏同种异体移植物的攻击。将诱导耐受的受体的脾细胞用于过继转移研究。单独使用抗ICOS抗体并不能延长心脏同种异体移植物的存活时间。AdCTLA-4Ig单一疗法显著延长了心脏同种异体移植物的存活时间(第4组)。联合使用抗ICOS抗体和AdCTLA-4Ig,所有受体均实现了超过200天的长期移植物接受(第8组)。当对第4组耐受大鼠的供体品系皮肤移植物进行攻击时,皮肤被排斥,这也导致了原发性心脏同种异体移植物的排斥。第8组的受体也排斥供体品系皮肤移植物,但原发性心脏移植物未被排斥。这些受体接受来自供体品系的二次心脏移植物,但不接受第三方的。在第8组长期存活的受体外周血中显示出高比例的CD4+CD25+调节性T细胞,并且在过继转移研究中去除这些CD4+CD25+T细胞会加速二次照射受体中心脏移植物的排斥。目前的结果表明,抗ICOS抗体与AdCTLA-4Ig联合在大鼠心脏移植后能有效诱导稳定的免疫耐受,这是由CD4+CD25+调节性T细胞的诱导介导的。该策略可能对临床诱导移植耐受具有吸引力。